Build status - In Progress
Found 94 Vision Loss trials
A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.
This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events (MACE) in subjects with Acute Coronary Syndrome (diagnosed with STEMI or NSTEMI), who are receiving evidence-based medical therapy.
The purpose of this study is to compare the effects of atezolizumab plus tiragolumab versus atezolizumab plus placebo or double placebo on subjects with esophageal cancer who have had at least 2 cycles of chemoradiotherapy without progression of their disease. Subjects with unresectable, locally advanced esophageal cancer will receive either …
Achromatopsia is an inherited retinal disorder characterized by markedly reduced visual acuity, nystagmus, photoaversion (intolerance to bright light), a small central scotoma, eccentric viewing, and complete or severe loss of color discrimination. The genetic mutations of the disease can be established in the majority of individuals. Approximately 25% are caused …
A double-blind study to investigate efficacy and safety of buntanetap compared with placebo in participants with early PD
This is a multicenter, randomized, double-blind, placebo-controlled two-part trial in patients with FAP who have previously undergone a colectomy/proctocolectomy using the invesitgational product REC-4881.
This study plans to learn more about the use of Rucaparib maintenance therapy after completion of prior therapy for recurrent endometrial cancer. Rucaparib belongs to a drug class called PARP inhibitors. There are currently three drugs approved by the U.S. Food and Drug Administration (FDA) in the setting of ovarian …
This is a multi-center, randomized, double-blind, placebo-controlled study of safety and efficacy of ISIS 678354 in patients with FCS. Eligible patients will enter an approximately 4-week Screening Period and an approximately 2-week qualification period. Approximately 60 eligible patients will be randomized 1:1 to Cohort A (50 mg) or Cohort B …
The LTI-01-2001 study is a double-blind, placebo-controlled, Phase 2 study to evaluate LTI-01 (single-chain urokinase plasminogen activator, scuPA) in patients with infected, non-draining pleural effusions.
A Single-blind, Phase 2, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients with Hepatorenal Syndrome-Acute Kidney Injury
Please choose between Voice or SMS based delivery of verification code
or